Intas in pact with Spanish drug maker mAbxience to sell biosimilar etanercept in over 150 countries

Share this post on:

Intas Pharmaceuticals on Friday said it has entered into a licensing agreement with Spanish biopharma company mAbxience for marketing and distribution of the latter’s biosimilar Etanercept in more than 150 countries including Europe and US.

The financial terms of this licensing deal were not disclosed.

mAbxience, a majority-owned company of German drug maker Fresenius Kabi, also has partial ownership from Insud Pharma, will be responsible for the development, manufacturing, and supply of the Etanercept biosimilar.

Etanercept was approved for use over 20 years ago, offering patients a valuable therapeutic option for treating various autoimmune diseases.

According to IQVIA, global sales of Etanercept for the 12 months ending June 2023 is $11 billion.

The two of the patents in US for Enbrel, the branded version of Etanercept marketed by Amgen, are expected to expire only in November 2028. Sandoz, a generic unit of Novarstis and Samsung Bioepis, are locked in litigation over patents. The patents of Enbrel were already expired in the EU and many other countries, allowing for the entry of biosimilars.”Partnering up with mAbxience, who are known for their dedication to quality and innovation, aligns perfectly with our vision. Together, we aim to revolutionize the landscape of autoimmune disease treatment,” said Intas’ vice chairman, Binish Chudgar.

Intas has strong in-house biosimilar development and marketing capabilities with more than 15 products in the market.

Share this post on:

Leave a Reply

Your email address will not be published. Required fields are marked *